Aura Biosciences (AURA) Competitors

$8.01 -0.01 (-0.12%)

Closing price 03:59 PM Eastern

Extended Trading

$7.96 -0.04 (-0.56%)

As of 04:04 PM Eastern

AURA vs. STOK, BHC, SRPT, OCUL, and ADMA

Should you buy Aura Biosciences stock or one of its competitors? MarketBeat compares Aura Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Aura Biosciences include Stoke Therapeutics (STOK), Bausch Health Cos (BHC), Sarepta Therapeutics (SRPT), Ocular Therapeutix (OCUL), and ADMA Biologics (ADMA). These companies are all part of the "pharmaceutical products" industry.

How does Aura Biosciences compare to Stoke Therapeutics?

Aura Biosciences (NASDAQ:AURA) and Stoke Therapeutics (NASDAQ:STOK) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, valuation, institutional ownership, media sentiment, analyst recommendations, dividends and profitability.

Aura Biosciences has a beta of 0.37, suggesting that its stock price is 63% less volatile than the broader market. Comparatively, Stoke Therapeutics has a beta of 1.2, suggesting that its stock price is 20% more volatile than the broader market.

Stoke Therapeutics has higher revenue and earnings than Aura Biosciences. Stoke Therapeutics is trading at a lower price-to-earnings ratio than Aura Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aura Biosciences	N/A	N/A	-$106.19M	-$1.74	N/A
Stoke Therapeutics	$32.08M	60.90	-$6.89M	-$2.81	N/A

Aura Biosciences has a net margin of 0.00% compared to Stoke Therapeutics' net margin of -529.20%. Stoke Therapeutics' return on equity of -48.84% beat Aura Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aura Biosciences	N/A	-78.12%	-64.08%
Stoke Therapeutics	-529.20%	-48.84%	-42.27%

Aura Biosciences presently has a consensus price target of $20.00, indicating a potential upside of 149.69%. Stoke Therapeutics has a consensus price target of $41.83, indicating a potential upside of 33.36%. Given Aura Biosciences' higher possible upside, equities analysts clearly believe Aura Biosciences is more favorable than Stoke Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aura Biosciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Stoke Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

In the previous week, Stoke Therapeutics had 5 more articles in the media than Aura Biosciences. MarketBeat recorded 22 mentions for Stoke Therapeutics and 17 mentions for Aura Biosciences. Stoke Therapeutics' average media sentiment score of 0.37 beat Aura Biosciences' score of -0.41 indicating that Stoke Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aura Biosciences	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Stoke Therapeutics	1 Very Positive mention(s)	3 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

96.8% of Aura Biosciences shares are held by institutional investors. 6.3% of Aura Biosciences shares are held by company insiders. Comparatively, 9.5% of Stoke Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Stoke Therapeutics beats Aura Biosciences on 10 of the 15 factors compared between the two stocks.

How does Aura Biosciences compare to Bausch Health Cos?

Bausch Health Cos (NYSE:BHC) and Aura Biosciences (NASDAQ:AURA) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, media sentiment, earnings and risk.

Bausch Health Cos has higher revenue and earnings than Aura Biosciences. Aura Biosciences is trading at a lower price-to-earnings ratio than Bausch Health Cos, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bausch Health Cos	$10.53B	0.19	$157M	-$3.24	N/A
Aura Biosciences	N/A	N/A	-$106.19M	-$1.74	N/A

78.7% of Bausch Health Cos shares are owned by institutional investors. Comparatively, 96.8% of Aura Biosciences shares are owned by institutional investors. 20.7% of Bausch Health Cos shares are owned by insiders. Comparatively, 6.3% of Aura Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Bausch Health Cos has a beta of 0.42, suggesting that its share price is 58% less volatile than the broader market. Comparatively, Aura Biosciences has a beta of 0.37, suggesting that its share price is 63% less volatile than the broader market.

Aura Biosciences has a net margin of 0.00% compared to Bausch Health Cos' net margin of -11.47%. Aura Biosciences' return on equity of -78.12% beat Bausch Health Cos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bausch Health Cos	-11.47%	-2,922.77%	5.63%
Aura Biosciences	N/A	-78.12%	-64.08%

In the previous week, Aura Biosciences had 12 more articles in the media than Bausch Health Cos. MarketBeat recorded 17 mentions for Aura Biosciences and 5 mentions for Bausch Health Cos. Bausch Health Cos' average media sentiment score of 0.08 beat Aura Biosciences' score of -0.41 indicating that Bausch Health Cos is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bausch Health Cos	0 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Aura Biosciences	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Bausch Health Cos currently has a consensus target price of $8.00, suggesting a potential upside of 46.65%. Aura Biosciences has a consensus target price of $20.00, suggesting a potential upside of 149.69%. Given Aura Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Aura Biosciences is more favorable than Bausch Health Cos.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bausch Health Cos	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80
Aura Biosciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Summary

Aura Biosciences beats Bausch Health Cos on 8 of the 15 factors compared between the two stocks.

How does Aura Biosciences compare to Sarepta Therapeutics?

Sarepta Therapeutics (NASDAQ:SRPT) and Aura Biosciences (NASDAQ:AURA) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, analyst recommendations, media sentiment, dividends, risk, earnings, valuation and institutional ownership.

Aura Biosciences has lower revenue, but higher earnings than Sarepta Therapeutics. Sarepta Therapeutics is trading at a lower price-to-earnings ratio than Aura Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sarepta Therapeutics	$2.20B	0.90	-$713.41M	-$0.96	N/A
Aura Biosciences	N/A	N/A	-$106.19M	-$1.74	N/A

86.7% of Sarepta Therapeutics shares are held by institutional investors. Comparatively, 96.8% of Aura Biosciences shares are held by institutional investors. 6.9% of Sarepta Therapeutics shares are held by insiders. Comparatively, 6.3% of Aura Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Sarepta Therapeutics has a beta of 0.26, suggesting that its stock price is 74% less volatile than the broader market. Comparatively, Aura Biosciences has a beta of 0.37, suggesting that its stock price is 63% less volatile than the broader market.

Aura Biosciences has a net margin of 0.00% compared to Sarepta Therapeutics' net margin of -2.94%. Sarepta Therapeutics' return on equity of 7.56% beat Aura Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sarepta Therapeutics	-2.94%	7.56%	2.94%
Aura Biosciences	N/A	-78.12%	-64.08%

In the previous week, Aura Biosciences had 5 more articles in the media than Sarepta Therapeutics. MarketBeat recorded 17 mentions for Aura Biosciences and 12 mentions for Sarepta Therapeutics. Sarepta Therapeutics' average media sentiment score of 0.29 beat Aura Biosciences' score of -0.41 indicating that Sarepta Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sarepta Therapeutics	1 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Aura Biosciences	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Sarepta Therapeutics presently has a consensus target price of $27.71, suggesting a potential upside of 48.13%. Aura Biosciences has a consensus target price of $20.00, suggesting a potential upside of 149.69%. Given Aura Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Aura Biosciences is more favorable than Sarepta Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sarepta Therapeutics	6 Sell rating(s)	13 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.11
Aura Biosciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Summary

Aura Biosciences beats Sarepta Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Aura Biosciences compare to Ocular Therapeutix?

Aura Biosciences (NASDAQ:AURA) and Ocular Therapeutix (NASDAQ:OCUL) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, valuation, analyst recommendations, risk, media sentiment, earnings, dividends and institutional ownership.

Aura Biosciences has higher earnings, but lower revenue than Ocular Therapeutix. Ocular Therapeutix is trading at a lower price-to-earnings ratio than Aura Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aura Biosciences	N/A	N/A	-$106.19M	-$1.74	N/A
Ocular Therapeutix	$52.04M	39.95	-$265.94M	-$1.46	N/A

96.8% of Aura Biosciences shares are held by institutional investors. Comparatively, 59.2% of Ocular Therapeutix shares are held by institutional investors. 6.3% of Aura Biosciences shares are held by company insiders. Comparatively, 2.3% of Ocular Therapeutix shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Aura Biosciences presently has a consensus target price of $20.00, suggesting a potential upside of 149.69%. Ocular Therapeutix has a consensus target price of $23.78, suggesting a potential upside of 150.42%. Given Ocular Therapeutix's stronger consensus rating and higher probable upside, analysts plainly believe Ocular Therapeutix is more favorable than Aura Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aura Biosciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Ocular Therapeutix	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79

Aura Biosciences has a beta of 0.37, suggesting that its share price is 63% less volatile than the broader market. Comparatively, Ocular Therapeutix has a beta of 0.93, suggesting that its share price is 7% less volatile than the broader market.

In the previous week, Aura Biosciences had 4 more articles in the media than Ocular Therapeutix. MarketBeat recorded 17 mentions for Aura Biosciences and 13 mentions for Ocular Therapeutix. Ocular Therapeutix's average media sentiment score of 0.19 beat Aura Biosciences' score of -0.41 indicating that Ocular Therapeutix is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aura Biosciences	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ocular Therapeutix	1 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Aura Biosciences has a net margin of 0.00% compared to Ocular Therapeutix's net margin of -558.24%. Ocular Therapeutix's return on equity of -64.28% beat Aura Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aura Biosciences	N/A	-78.12%	-64.08%
Ocular Therapeutix	-558.24%	-64.28%	-48.15%

Summary

Ocular Therapeutix beats Aura Biosciences on 9 of the 15 factors compared between the two stocks.

How does Aura Biosciences compare to ADMA Biologics?

ADMA Biologics (NASDAQ:ADMA) and Aura Biosciences (NASDAQ:AURA) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and media sentiment.

ADMA Biologics has higher revenue and earnings than Aura Biosciences. Aura Biosciences is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ADMA Biologics	$509.86M	3.97	$146.93M	$0.68	12.50
Aura Biosciences	N/A	N/A	-$106.19M	-$1.74	N/A

75.7% of ADMA Biologics shares are owned by institutional investors. Comparatively, 96.8% of Aura Biosciences shares are owned by institutional investors. 3.9% of ADMA Biologics shares are owned by insiders. Comparatively, 6.3% of Aura Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

ADMA Biologics currently has a consensus target price of $19.00, suggesting a potential upside of 123.61%. Aura Biosciences has a consensus target price of $20.00, suggesting a potential upside of 149.69%. Given Aura Biosciences' higher possible upside, analysts plainly believe Aura Biosciences is more favorable than ADMA Biologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ADMA Biologics	0 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.40
Aura Biosciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

ADMA Biologics has a beta of 0.83, suggesting that its share price is 17% less volatile than the broader market. Comparatively, Aura Biosciences has a beta of 0.37, suggesting that its share price is 63% less volatile than the broader market.

In the previous week, ADMA Biologics and ADMA Biologics both had 17 articles in the media. ADMA Biologics' average media sentiment score of 0.26 beat Aura Biosciences' score of -0.41 indicating that ADMA Biologics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ADMA Biologics	3 Very Positive mention(s)	1 Positive mention(s)	10 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Aura Biosciences	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

ADMA Biologics has a net margin of 32.43% compared to Aura Biosciences' net margin of 0.00%. ADMA Biologics' return on equity of 39.98% beat Aura Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ADMA Biologics	32.43%	39.98%	28.08%
Aura Biosciences	N/A	-78.12%	-64.08%

Summary

ADMA Biologics beats Aura Biosciences on 9 of the 13 factors compared between the two stocks.

Get Aura Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AURA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AURA vs. The Competition

Export

Metric	Aura Biosciences	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$514.24M	$3.40B	$6.29B	$12.46B
Dividend Yield	N/A	2.31%	2.79%	5.30%
P/E Ratio	-4.60	18.81	20.87	25.61
Price / Sales	N/A	181.76	521.62	63.45
Price / Cash	N/A	122.51	42.94	55.34
Price / Book	4.80	6.75	9.86	6.71
Net Income	-$106.19M	$24.11M	$3.55B	$333.77M
7 Day Performance	-2.32%	0.11%	-0.26%	0.40%
1 Month Performance	12.98%	0.87%	1.39%	4.03%
1 Year Performance	63.47%	78.18%	41.07%	36.33%

Aura Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AURA Aura Biosciences	2.2004 of 5 stars	$8.01 -0.1%	$20.00 +149.7%	+52.5%	$514.24M	N/A	N/A	50	Earnings Report Upcoming Earnings Analyst Forecast Insider Trade Analyst Revision
STOK Stoke Therapeutics	2.4007 of 5 stars	$32.49 -0.5%	$41.83 +28.8%	+255.0%	$2.02B	$184.42M	N/A	100	Earnings Report Analyst Forecast Analyst Revision
BHC Bausch Health Cos	2.3941 of 5 stars	$5.41 +0.7%	$8.00 +48.0%	+12.7%	$2.02B	$10.27B	N/A	20,300
SRPT Sarepta Therapeutics	3.459 of 5 stars	$19.13 -1.4%	$27.71 +44.8%	-48.0%	$2.02B	$2.20B	N/A	1,372	Gap Up
OCUL Ocular Therapeutix	3.6172 of 5 stars	$9.16 -1.3%	$23.78 +159.6%	+32.0%	$2.01B	$51.95M	N/A	230

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AURA) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Aura Biosciences (AURA) Competitors

AURA vs. STOK, BHC, SRPT, OCUL, and ADMA

How does Aura Biosciences compare to Stoke Therapeutics?

Summary

How does Aura Biosciences compare to Bausch Health Cos?

Summary

How does Aura Biosciences compare to Sarepta Therapeutics?

Summary

How does Aura Biosciences compare to Ocular Therapeutix?

Summary

How does Aura Biosciences compare to ADMA Biologics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AURA vs. The Competition

Aura Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Aura Biosciences (AURA) Competitors

AURA vs. STOK, BHC, SRPT, OCUL, and ADMA

How does Aura Biosciences compare to Stoke Therapeutics?

Which has more volatility and risk, AURA or STOK?

Which has stronger valuation and earnings, AURA or STOK?

Is AURA or STOK more profitable?

Do analysts rate AURA or STOK?

Does the media favor AURA or STOK?

Do institutionals & insiders have more ownership in AURA or STOK?

Summary

How does Aura Biosciences compare to Bausch Health Cos?

Which has better earnings and valuation, BHC or AURA?

Do institutionals and insiders have more ownership in BHC or AURA?

Which has more volatility and risk, BHC or AURA?

Is BHC or AURA more profitable?

Does the media refer more to BHC or AURA?

Do analysts prefer BHC or AURA?

Summary

How does Aura Biosciences compare to Sarepta Therapeutics?

Which has preferable earnings & valuation, SRPT or AURA?

Do insiders & institutionals have more ownership in SRPT or AURA?

Which has more risk and volatility, SRPT or AURA?

Is SRPT or AURA more profitable?

Does the media prefer SRPT or AURA?

Do analysts prefer SRPT or AURA?

Summary

How does Aura Biosciences compare to Ocular Therapeutix?

Which has higher earnings and valuation, AURA or OCUL?

Do institutionals & insiders have more ownership in AURA or OCUL?

Do analysts prefer AURA or OCUL?

Which has more risk & volatility, AURA or OCUL?

Does the media prefer AURA or OCUL?

Is AURA or OCUL more profitable?

Summary

How does Aura Biosciences compare to ADMA Biologics?

Which has preferable valuation & earnings, ADMA or AURA?

Do institutionals and insiders hold more shares of ADMA or AURA?

Do analysts prefer ADMA or AURA?

Which has more risk & volatility, ADMA or AURA?

Does the media refer more to ADMA or AURA?

Is ADMA or AURA more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AURA vs. The Competition

Aura Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools